key: cord-0706006-y2wnskkm
authors: Tegeler, Christian M.; Bilich, Tatjana; Maringer, Yacine; Salih, Helmut R.; Walz, Juliane S.; Nelde, Annika; Heitmann, Jonas S.
title: Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort
date: 2022-04-14
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2022.04.019
sha: 770cfd80c22ed8b1942dd81552e37e8240f759e0
doc_id: 706006
cord_uid: y2wnskkm

Objective Besides SARS-CoV-2-directed humoral immune responses, T cell responses are indispensable for effective anti-viral immunity. Recent data have shown a correlation of COVID-19 symptoms with humoral immune response, but so far little is known on the association of SARS-CoV-2-directed T cell responses and disease severity. We here evaluated the prevalence of different clinical COVID-19 symptoms in relation to SARS-CoV-2-directed humoral and cellular immune responses. Methods Severity of eight different symptoms during acute infection were assessed questionnaire-based from 193 convalescent individuals and evaluated in relation to SARS-CoV-2 antibody levels and intensity of SARS-CoV-2-specific T cell responses 2 - 8 weeks after positive PCR. Results Whereas increased IgG serum levels could be associated with severity of most symptoms, no difference in T cell response intensity between different symptom severities was observed for the majority of COVID-19 symptoms. However, when analyzing loss of smell or taste and cough, awareness of more severe symptoms was associated with reduced T cell response intensities. Conclusion These data suggest that rapid virus clearance mediated by SARS-CoV-2-specific T cells prevents severe symptoms of COVID-19.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces highly variable clinical manifestations of coronavirus disease 2019 , ranging from asymptomatic infections or mild disease characteristics to severe and even life-threatening courses of disease (García, 2020) . Infected individuals present with a variety of different disease symptoms, comprising fever, fatigue, loss of smell and taste, cough, headache, and/or dyspnea . Based on the manifestations of these symptoms, patients are categorized in different disease severity groups (Son et al., 2021) with most patients experiencing mild symptoms not requiring medical intervention or hospitalization (Nakamichi et al., 2021) . After relief of symptoms, patients are considered to be protected from reinfection for several months mediated by the immunological memory of the humoral and cellular immune system . The humoral immune response, i.e. SARS-CoV-2-specific antibodies, detected in convalescent individuals has led to the approval of immune therapeutics like the REGN-COV2 antibody cocktail (Weinreich et al., 2021) , and prophylactic vaccines, which aim to induce a protective immune response (Polack et al., 2020) . Whereas most infected individuals remain asymptomatic or show mild symptoms and mount a potent immune response, others suffer from a severe course of disease with a dysregulated immune reaction (Kowalik et al., 2020 , Krämer et al., 2021 . A plethora of data is available regarding the characteristics of humoral and cellular immune responses in SARS-CoV-2-infected individuals (Altmann and Boyton, 2020 , Bilich et al., 2021a , Bilich et al., 2021b , Brunk et al., 2021 , Jarjour et al., 2021 , Kared et al., 2021 , Karlsson et al., 2020 , Sekine et al., 2020 , Woldemeskel et al., 2020 , Woodruff et al., 2020 .

Whereas antibody titers have been reported to be increased in patients with more severe COVID-19 (Woodruff et al., 2020) , so far, little is known about the correlation of T cell responses with clinical symptoms. T cells are not only central for immune modulation and for guiding B cells to produce antibodies, but also play an important role in virus clearance by direct killing of SARS-CoV-2-infected cells (Grifoni et al., 2020 , Kared et al., 2021 .

Here, we studied COVID-19 course of 193 individuals during asymptomatic to moderate SARS-CoV-2 infection and their association with SARS-CoV-2-specific antibody and T cell responses up to 59 days after acute infection. The documented differences in symptom severity and immune response provide insights into the role of T cell immunity against SARS-CoV-2 for the occurrence and severity of clinical symptoms.

Blood and serum samples as well as questionnaire-based assessment of donor characteristics and disease symptoms from convalescent volunteers after asymptomatic to moderate symptomatic SARS-CoV-2 infection (n = 193) were collected at the University Hospital Tübingen from April to July 2020. Informed consent was obtained in accordance with the Declaration of Helsinki protocol. The study was approved by and performed according to the guidelines of the local ethics committees (179/2020/BO2). SARS-CoV-2 infection was confirmed by polymerase chain reaction (PCR) test after nasopharyngeal swab. Donor recruitment was performed by online and paper-based advertising (homepage, flyer). Sample collection in terms of peripheral blood mononuclear cells (PBMCs) and serum was performed approximately 3 -8 weeks after the end of symptoms and/or negative virus smear. Symptom categories were determined by subjective disease symptoms (no, mild, moderate, and severe, reported by questionnaire) of individual donors. Detailed donor characteristics and distribution of symptom severity are provided in Tables 1 and 2 .

Data on SARS-CoV-2-specific T cell responses assessed by interferon-γ (IFN-γ) enzyme-linked immunospot (ELISpot) assay, anti-SARS-CoV-2 nucleocapsid antibody titers assessed by Elecsys® anti-SARS-CoV-2 immunoassay (Roche Diagnostics) and anti-SARS-CoV-2 spike antibody titers assessed by Euroline Anti-SARS-CoV-2® (Euroimmune) were retrieved from a previous publication . For this analysis, we considered SARS-CoV-2-specific T cell response intensities against the previously described SARS-CoV-2-specific epitope compositions for HLA class I and HLA-DR. These SARS-CoV-2-specific epitope compositions were designed from immunogenic SARS-CoV-2-derived T cell epitopes derived from different open reading frames (ORF), including spike, nucleocapsid, and membrane proteins, and recognized exclusively in convalescent patients after SARS-CoV-2 infection and not in SARS-CoV-2 unexposed individuals. The HLA class I and HLA-DR epitope compositions cover several different HLA class I and HLA-DR allotypes, respectively, to allow for standardized evaluation and determination of intensities of SARS-CoV-2-specific T cell responses. The intensity of T cell responses was measured as mean spot counts of duplicates in the ELISpot assay normalized to 5 × 10 5 cells minus the normalized mean spot count of the respective negative control.

Data are displayed as mean with standard deviation (SD), box plots as median with 25th or 75th quantiles and min/max whiskers. Continuous data were tested for distribution and individual groups were tested by use of an unpaired Mann-Whitney U-test or Kruskal-Wallis test and corrected for multiple comparison, if applicable. Missing data were included in tables and in descriptive analysis. Graphs were plotted using GraphPad Prism v.9.1.2. Statistical analyses were conducted using JMP Pro (SAS Institute, v.15) software. P-values < 0.05 were considered statistically significant.

For this study, we analyzed clinical symptoms and SARS-CoV-2-specific antibody and T cell response data of 193 convalescent donors with an asymptomatic to moderate COVID-19 course.

None of the donors was hospitalized, had severe/life-threatening symptoms according to the WHO criteria (Son et al., 2021) or was vaccinated prior to SARS-CoV-2 infection. It is assumed that all infections were caused by the wild type of SARS-CoV-2, although samples were not sequenced. Antibody and T cell responses were assessed 16 -59 days (median 40.5 days) after positive PCR . Mean age of convalescents was 43.3 (SD ± 14) years. The male:female ratio was nearly equally distributed with 1:1.2. As expected, subjective symptom severity was heterogeneously distributed. The most frequent symptoms were "feel sick" (93%), followed by "fatigue" (86%). 6% of study participants had reported no symptoms. Individuals experiencing "loss of smell or taste" or "fatigue" graded these symptoms mostly severe (45% and 36% of all convalescents, respectively). Interestingly, only two convalescents reported severe dyspnea according to questionnaire. Clinical data and details regarding distribution of severity of the respective symptom groups are presented in Tables 1 and 2 .

As a first step, we compared anti-nucleocapsid-SARS-CoV-2 antibody titers of convalescent donors with severity of subjective COVID-19 symptoms. In case of the symptom "feel sick", antibody titers were significantly higher in severe compared to asymptomatic, mild, and moderate cases (p-value 0.0043, 0.0023, and 0.044, respectively; Fig   1A) . Regarding "cough", there was a tendency for higher IgG titers in convalescents experiencing severe symptoms compared to other severity grades, but without reaching statistical significance ( Fig 1B) . Antibody titers were significantly higher in convalescents reporting mild, moderate, and severe "fever" compared to asymptomatic cases (p-value 0.0003, <0.0001, and 0.0013, respectively; Fig 1C) . Individuals with no and mild "sore throat" had significantly higher antibody titers compared to individuals with moderate symptoms (p-value 0.013 and 0.014, respectively; Fig 1D) . Convalescents with severe "headache" showed significantly higher antibody levels than convalescents with no, mild, or moderate symptoms (p-value 0.011, 0.049, and 0.013, respectively; Fig 1E) . In individuals reporting "loss of smell or taste", IgG levels were significantly higher for convalescents with severe than for those with no symptoms (p-value 0.0002; Fig 1F) . Considering "shortness of breath", no significant difference between asymptomatic, mild, moderate, and severe symptoms was observed ( Fig 1G) . Convalescents experiencing severe or moderate "fatigue" had significantly higher IgG levels than convalescents without fatigue (p-value 0.016 and 0.026, respectively; Fig 1H) . Additionally, we compared antispike-SARS-CoV-2 antibody titers of convalescent donors with severity of subjective COVID-19 symptoms. Antibody titers were significantly higher in convalescents reporting severe manifestation of all assessed symptoms compared to asymptomatic individuals ( Supplementary Fig 1) . Taken together, anti-nucleocapsid IgG levels were significantly higher in individuals reporting severe manifestation of the symptoms "feel sick", "fever", "headache", "loss of smell or taste" and "fatigue" compared to individuals without these symptoms, whereas anti-spike antibody titers differed for all assessed symptoms.

Next, we compared the severity of COVID-19 symptoms with the intensity of SARS-CoV-2specific T cell responses for HLA class I-and HLA-DR-restricted T cell epitopes, assessed by IFN-γ ELISpot assay using SARS-CoV-2-specific epitope compositions in PBMC samples of SARS-CoV-2 convalescents . Intensity of HLA class I and HLA-DR T cell responses did not differ for the severity of the symptom "feel sick" (Fig 2A) . Convalescent donors with moderate "cough" had a significantly decreased intensity of T cell responses to HLA class I epitope compositions in comparison to convalescents experiencing mild or no symptoms (p-value 0.0049 and 0.031, respectively; Fig 2B) . Of note, convalescents with mild "cough" displayed significantly increased intensity of HLA-DR T cell responses compared to asymptomatic convalescents or convalescents experiencing moderate "cough" (p-value 0.014 or 0.041, respectively; Fig 2B) . Regarding the severity of "fever", T cell responses to HLA class I epitope compositions were found to be significantly decreased in severe compared to mild cases (p-value 0.031; Fig 2C) . This was not observed for T cell responses to HLA-DR epitope compositions ( Fig 2C) . In individuals experiencing "sore throat" and "headache", the intensity of T cell response did not differ between symptom grades for HLA class I and HLA-DR epitope compositions (Fig 2D and E) . When grouped according to the severity of "loss of smell or taste", T cell responses to HLA class I epitope composition were significantly decreased in severe compared to mild cases (p-value 0.031; Fig 2F) . In contrast, T cell responses to HLA-DR epitope composition were not different between the four categories of severity ( Fig 2F) . Intensity of HLA class I and HLA-DR T cell responses showed no significant difference between symptom severity categories for "shortness of breath" and "fatigue" (Fig 2G and H) . Of note, when dividing the study population according to the time of sample collection (cut-off median: 42 days) into two groups, we did not observe higher HLA class I nor HLA-DR T cell response at the earlier time point (Supplementary Fig 2) . In summary, no difference in T cell response intensity between different symptom severities was observed for the majority of COVID-19 symptoms.

However, for "loss of smell or taste" and "cough", awareness of more severe symptoms was associated with lower HLA class I-restricted T cell response intensities.

When symptom severity was grouped in asymptomatic versus symptomatic (mild/moderate/severe), anti-nucleocapsid antibody titers differed significantly for "feel sick", "fever", "loss of smell or taste" and "fatigue" (p-value 0.048, <0.0001, 0.0003, and 0.0023, respectively; Table 3 ). When analyzing the humoral response in symptomatic convalescent donors (mild versus moderate/severe symptoms), no significant difference was observed for most symptoms except for "feel sick" showing increased anti-nucleocapsid antibody titers in moderate/severe cases (p-value 0.013; Table 4 ).

T cell responses did not differ significantly between asymptomatic and symptomatic (mild/moderate/severe) participants (Tables 5 and 6 ). Analyzing T cell responses in symptomatic convalescents (mild versus moderate/severe symptoms) revealed no significant difference for most symptoms (Fig 3) , except for "cough" and "loss of smell or taste" where the intensity of HLA class I T cell responses was significantly decreased in moderate/severe cases (p-value 0.0095 and 0.025, respectively; Fig 3B and F) . Similar results were observed for the symptom "cough" regarding T cell responses to HLA-DR epitope compositions but failed to reach statistical significance (Fig 3B) .

COVID-19 patients present with a variety of symptoms, ranging from asymptomatic infections or mild to severe courses of disease, potentially being also life-threatening and lethal , Miller and Yan, 2021 . Patients suffering from severe COVID-19 according to the WHO grading scale (Son et al., 2021) have been reported to develop a potent humoral immune response with high antibody titers against SARS-CoV-2 (Horton et al., 2021 . In this study, we are the first to report on the association between symptom severity of subjective symptoms in 193 individuals with asymptomatic SARS-CoV-2 infection or mild to moderate COVID-19 according to WHO (Son et al., 2021) and humoral and cellular immune responses to SARS-CoV-2 by assessing both, serum antibody titers as well as SARS-CoV-2-specific T cell responses. "Feel sick" and "fatigue" were the most reported symptoms in our cohort, which had also been reported in other large cohort studies (Bakılan et al., 2021) . In line with recent data, reporting on elevated anti-spike antibody levels in severe/lifethreatening COVID-19 in hospitalized patients (Horton et al., 2021 , Woodruff et al., 2020 , we found serum anti-nucleocapsid antibody levels to increase with more severe COVID-19 for most symptoms and serum anti-spike antibody levels to increase with more severe COVID-19 for all symptoms. In contrast, T cell immune responses decreased or showed no difference between the severity of COVID-19 cases (Toor et al., 2021) . These results indicate that the extent of the humoral immune response appears to associate also with the severity of subjective symptoms in mild COVID-19 cases. Assessment of humoral immune responses to SARS-CoV-2 could therefore allow for the identification of asymptomatic individuals or patients with mild COVID-19, who would profit from early vaccination after recovery. This is supported by further data on SARS-CoV-2 antibodies in convalescent individuals, showing a decline in antibody titers already a few weeks to months after infection (Bilich et al., 2021a , Haveri et al., 2021 , Van Elslande et al., 2021 . Assuming a linear decline, patients with high antibody titers would remain seropositive longer than those with initially lower antibody titers. This suggests that patients with asymptomatic or mild COVID-19 are more likely to be earlier seronegative for SARS-CoV-2 antibodies after infection. Whereas antibody titers have been shown to rapidly decrease after infection (Marot et al., 2021) , T cell responses appear to persist longer (Altmann and Boyton, 2020, Bilich et al., 2021a) and, in case of SARS-CoV-1, were still measurable up to 17 years after infection (Anderson et al., 2020) .

So far, the humoral immune response to SARS-CoV-2 is used to determine previous infection as well as anti-viral immunity after vaccination (Polack et al., 2020) . The underlying reason for elevated antibody titers in patients suffering from severe COVID-19 is so far not fully understood and is considered to be the result of a more pronounced immune activation. A dysregulated immune response resulting in antibody-dependent enhancement (ADE) has been described for SARS-CoV-1-infected patients (Karthik et al., 2020 , Negro, 2020 , and might also contribute to disease severity in COVID-19.

symptoms (Kim et al., 2021) . We here employed previously reported data on SARS-CoV-2specific T cell responses against HLA class I-and HLA-DR-restricted SARS-CoV-2-derived epitope compositions for a respective correlative study. Interestingly, and in contrast to humoral immune responses, intensities of T cell responses were found to be in most cases not associated with symptom severity, or were even decreased in individuals with worse symptoms. This held true for both, HLA class I-and HLA-DR-restricted T cell responses, indicating that a broad T cell response is induced even after mild disease symptoms. One might speculate that a more symptomatic disease is triggered and enhanced by negative effects of antibody response (Karthik et al., 2020 , Negro, 2020 , while early viral clearance by T cells might protect against a worse disease course.

A major problem of COVID-19 is the potential persistence of long-term symptoms (Huang et al., 2021 , Mendelson et al., 2020 , which could be due to a dysregulated or overactive immune response. Whether intensity and characteristics of T cell or antibody responses are associated with occurrence of long-term symptoms is yet unclear, but constitutes an important question.

Our study population represents the majority of all COVID-19 cases, including asymptomatic to moderate cases according to WHO classification (Jiang et al., 2020 , Mulchandani et al., 2021 , Sattler et al., 2020 . The severity of disease symptoms, however, was assessed by a questionnaire, which of course has to be taken with caution due to non-objective individual selfassessment (Maddox and Douglass, 1973, Ward et al., 2002) . In conclusion, we showed that in contrast to antibody responses, SARS-CoV-2-directed T cell responses are not elevated in severe COVID-19 cases, but are equally strong for different disease severities highlighting the strength of T cell-based immunity for viral clearance. The intensity of T cell responses is depicted as mean spot counts of duplicates in the ELISpot assay normalized to 5 × 10 5 cells minus the normalized mean spot count of the respective negative control. 

SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection

Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2

Musculoskeletal symptoms and related factors in postacute COVID-19 patients

T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals

Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer

SARS-CoV-2-reactive T-cell receptors isolated from convalescent COVID-19 patients confer potent T-cell effector function

Immune Response, Inflammation, and the Clinical Spectrum of COVID-19

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans

Determinants and dynamics of SARS-CoV-2 infection in a diverse population: 6-month evaluation of a prospective cohort study

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

T Cell Memory: Understanding COVID-19

COVID-19 pneumonia: CD8(+) T and NK cells are decreased in number but compensatory increased in cytotoxic potential

SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals

The known unknowns of T cell immunity to COVID-19

Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19

SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity

COVID-19 -Toward a comprehensive understanding of the disease

Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19

COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Self-assessment of health: a longitudinal study of elderly subjects

Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers

Long-COVID: An evolving problem with an extensive impact

COVID-19 Gastrointestinal Symptoms and Attenuation of the Immune Response to SARS-CoV-2

Deciphering the COVID-19 cytokine storm: Systematic review and meta-analysis

Hospitalization and mortality associated with SARS-CoV-2 viral clades in COVID-19

Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China

SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient predisposition

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Disease severity classification and COVID-19 outcomes, Republic of Korea

Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection

T-cell responses and therapies against SARS-CoV-2 infection

Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection

Measuring self-assessment: current state of the art

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2

Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19

Clinical characteristics of 3062 COVID-19 patients: A meta-analysis

Symptomatic convalescent individuals reported mild, moderate or severe symptoms. n: number of donors. SD: standard deviation; p-values calculated with Mann-Whitney-U test. The intensity of T cell responses is depicted as mean

We thank all donors for their support of our research. We thank all technicians for technical support and project coordination. This work was supported by the Bundesministerium für 

A.N., T.B. and J.S.W. hold patents on peptides described in this manuscript secured under the numbers 20_169_047.6 and 20_190_070.1. The other authors declare no competing interests.The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.